-
Mashup Score: 23Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease - 2 month(s) ago
Objective Lipoprotein(a) (Lp(a)) is an important genetically determined risk factor for atherosclerotic vascular disease (ASCVD). With the development of Lp(a)-lowering therapies, this study sought to characterise patterns of Lp(a) levels in a global ASCVD population and identify racial, ethnic, regional and gender differences. Methods A multicentre cross-sectional epidemiological study to estimate the prevalence of elevated Lp(a) in patients with a history of myocardial infarction, ischaemic stroke or peripheral artery disease conducted at 949 sites in 48 countries in North America, Europe, Asia, South America, South Africa and Australia between April 2019 and July 2021. Low-density lipoprotein cholesterol (LDL-C) and Lp(a) levels were measured either as mass (mg/dL) or molar concentration (nmol/L). Results Of 48 135 enrolled patients, 13.9% had prior measurements of Lp(a). Mean age was 62.6 (SD 10.1) years and 25.9% were female. Median Lp(a) was 18.0 mg/dL (IQR 7.9–57.1) or 42.0 nmol
Source: openheart.bmj.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease - 6 month(s) ago
Atherosclerotic cardiovascular disease (ASCVD) is the world’s leading cause of death. ASCVD has multiple mediators that therapeutic interventions target, such as dyslipidaemia,
Source: www.ecrjournal.comCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0Pooled Cohort Equations Work in Real-world Patients, Even Outliers - 6 month(s) ago
The risk prediction tool performed well for all subgroups, as well as for those on statins or with values outside of normal ranges.
Source: www.tctmd.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6Hot Topics in Cardiovascular Disease: Can Cardiologists Do More to Improve Outcomes in People with Type 2 Diabetes? - 7 month(s) ago
Cardiologists, get the education while it’s hot! Learn about recent cardiology recommendations for managing people with type 2 diabetes.
Source: www.medscape.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Cardiologists, enhance T2D outcomes! GLP-1RAs now advised for high #ASCVD risk, irrespective of A1C or metformin. Learn data and tips for confident treatment planning. 🩺 https://t.co/YELaDijSwH #cme #MedTwitter #MedX https://t.co/zxgX6kmC6u
-
-
Mashup Score: 7Hot Topics in Cardiovascular Disease: Can Cardiologists Do More to Improve Outcomes in People with Type 2 Diabetes? - 7 month(s) ago
Cardiologists, get the education while it’s hot! Learn about recent cardiology recommendations for managing people with type 2 diabetes.
Source: www.medscape.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Cardiologists, enhance T2D outcomes! GLP-1RAs now advised for high #ASCVD risk, irrespective of A1C or metformin. Learn data and tips for confident treatment planning. 🩺 https://t.co/nRiJzKGZbs #cme #MedTwitter #MedX https://t.co/ar6j0iUOTz
-
-
Mashup Score: 3New Study: Much-Maligned Equation Accurately Assesses ASCVD Risk in Real-World Practice - 7 month(s) ago
A new study shows that the oft-questioned pooled cohort equation (PCE) accurately assesses the risk of atherosclerotic cardiovascular disease (ASCVD) in a community cohort representing real-world clin
Source: www.crtonline.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Back to the Future: Revitalizing the Role of Cholesteryl Ester Transfer Protein (CETP) Inhibition for CV Risk Reduction - 7 month(s) ago
What is CETP inhibition, and can it be the answer to further lowering risk in patients with atherosclerotic cardiovascular disease (ASCVD)?
Source: www.medscape.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 4
The Multilingual ASCVD Risk Estimator is a simplified web-based version of the ASCVD Risk Estimator Plus app that provides clinicians with an efficient way to calculate a patient’s estimated 10-year ASCVD risk, optimal risk and lifetime risk.
Source: www.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Biykem Bozkurt, MD, P h D, FACC Gurusher S. Panjrath, MBBS, FACC Javier A. Sala-Mercado, MD, P h D Megan Coylewright, MD, MPH, FACC – Ex Officio 1.1. Rationale for Expert Consensus Decision Pathway 1370 1.1.1. Newer Nonstatin Therapies 1370 3. Assumptions and Definitions 1380 4. Pathway Summary Graphic 1382 Figure 1. Summary Graphic: Patient Populations Addressed and Factors and Interventions to Consider 1383 5. Description And Rationale: Approach to Patient Groups Who May Be Considered for Additional
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0Back to the Future: Revitalizing the Role of Cholesteryl Ester Transfer Protein (CETP) Inhibition for CV Risk Reduction - 7 month(s) ago
What is CETP inhibition, and can it be the answer to further lowering risk in patients with atherosclerotic cardiovascular disease (ASCVD)?
Source: www.medscape.orgCategories: Latest Headlines, NeurologyTweet
Lipoprotein(a) levels in a global #ASCVD https://t.co/mRGOmmv9O3